Cover Image
市場調查報告書

Transthyretin:開發中產品分析

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251567
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
Transthyretin:開發中產品分析 Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 77 Pages
簡介

本報告提供Transthyretin的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

Transthyretin概要

治療藥的開發

Transthyretin:開發中的產品 - 各開發階段

Transthyretin:開發中的產品 - 各治療範圍

Transthyretin:開發中的產品 - 各適應症

Transthyretin:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Transthyretin:企業開發中的產品

Transthyretin:大學/機關開發中的產品

Transthyretin:治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Transthyretin的治療藥的開發企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Neurimmune Holding AG
  • Pfizer Inc.
  • Prothena Corporation Plc
  • Regeneron Pharmaceuticals, Inc.
  • SOM Innovation Biotech SL

藥物簡介

暫停中的計劃

主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0605TDB

Summary

Global Markets Direct's, 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2016', provides in depth analysis on Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted pipeline therapeutics.

The report provides comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) Overview 7
  • Therapeutics Development 8
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Stage of Development 8
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Therapy Area 9
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Indication 10
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Products Glance 11
  • Late Stage Products 11
  • Early Stage Products 12
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Companies 13
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Products under Development by Universities/Institutes 15
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment 17
  • Assessment by Monotherapy/Combination Products 17
  • Assessment by Mechanism of Action 18
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development 23
  • Alnylam Pharmaceuticals, Inc. 23
  • Arcturus Therapeutics, Inc. 24
  • Ionis Pharmaceuticals, Inc. 25
  • Neurimmune Holding AG 26
  • Pfizer Inc. 27
  • Prothena Corporation Plc 28
  • Regeneron Pharmaceuticals Inc 29
  • SOM Biotech SL 30
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles 31
  • ALN-TTRsc02 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • doxycycline hyclate - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • EDE-1307 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • inotersen sodium - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • LUNAR-TTR - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • NI-301 - Drug Profile 40
  • Product Description 40
  • Mechanism Of Action 40
  • R&D Progress 40
  • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • patisiran - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • PRX-004 - Drug Profile 50
  • Product Description 50
  • Mechanism Of Action 50
  • R&D Progress 50
  • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile 51
  • Product Description 51
  • Mechanism Of Action 51
  • R&D Progress 51
  • tafamidis meglumine - Drug Profile 52
  • Product Description 52
  • Mechanism Of Action 52
  • R&D Progress 52
  • tolcapone - Drug Profile 55
  • Product Description 55
  • Mechanism Of Action 55
  • R&D Progress 55
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Projects 57
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products 58
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Featured News & Press Releases 59
  • Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 59
  • Aug 08, 2016: Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease 59
  • Jul 07, 2016: Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis 60
  • Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis 62
  • Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis 64
  • Jun 09, 2016: Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis 65
  • May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program 65
  • Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 66
  • Apr 07, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program 68
  • Mar 16, 2016: Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid 69
  • Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 69
  • Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis 70
  • Nov 12, 2015: SOM Biotech and Vall d'Hebron successfully complete a clinical trial in patients with TTR amyloidosis 71
  • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 72
  • Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting 74
  • Appendix 76
  • Methodology 76
  • Coverage 76
  • Secondary Research 76
  • Primary Research 76
  • Expert Panel Validation 76
  • Contact Us 76
  • Disclaimer 77

List of Tables

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 11
  • Comparative Analysis by Early Stage Products, H2 2016 12
  • Number of Products under Development by Companies, H2 2016 13
  • Products under Development by Companies, H2 2016 14
  • Number of Products under Investigation by Universities/Institutes, H2 2016 15
  • Products under Investigation by Universities/Institutes, H2 2016 16
  • Assessment by Monotherapy/Combination Products, H2 2016 17
  • Number of Products by Stage and Mechanism of Action, H2 2016 18
  • Number of Products by Stage and Route of Administration, H2 2016 20
  • Number of Products by Stage and Molecule Type, H2 2016 22
  • Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 23
  • Pipeline by Arcturus Therapeutics, Inc., H2 2016 24
  • Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 25
  • Pipeline by Neurimmune Holding AG, H2 2016 26
  • Pipeline by Pfizer Inc., H2 2016 27
  • Pipeline by Prothena Corporation Plc, H2 2016 28
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 29
  • Pipeline by SOM Biotech SL, H2 2016 30
  • Dormant Projects, H2 2016 57
  • Discontinued Products, H2 2016 58

List of Figures

  • Number of Products under Development for, H2 2016 8
  • Number of Products under Development by Therapy Area, H2 2016 9
  • Number of Products under Development by Indication, H2 2016 10
  • Comparative Analysis by Late Stage Development, H2 2016 11
  • Comparative Analysis by Early Stage Products, H2 2016 12
  • Assessment by Monotherapy/Combination Products, H2 2016 17
  • Number of Products by Stage and Mechanism of Actions, H2 2016 18
  • Number of Products by Routes of Administration, H2 2016 19
  • Number of Products by Stage and Routes of Administration, H2 2016 19
  • Number of Products by Molecule Types, H2 2016 21
  • Number of Products by Stage and Molecule Type, H2 2016 21
Back to Top